Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage

Ewing sarcomas (ES) harbor a chromosomal translocation that fuses the EWS gene to an ETS transcription factor, most commonly Friend leukemia integration 1 (FLI1). The EWS-FLI1 fusion protein acts in a positive feedback loop to maintain the expression of PARP-1, which is involved in repair of DNA damage. Here, we examine the effects of PARP-1 inhibition and radiation therapy on Ewing sarcomas. In proliferation assays, the Ewing sarcoma cell lines RD-ES and SK-N-MC were much more sensitive than non-Ewing sarcoma cell lines to the PARP-1 inhibitor olaparib (Ola; IC50 0.5–1 μmol/L vs. >5 μmol/L) and to radiation (IC50 2–4 Gy vs. >6 Gy). PARP-1 inhibition with short hairpin RNA (shRNA) or Ola sensitized Ewing sarcoma cells, but not non-Ewing sarcoma cells, to radiation therapy in both proliferation and colony formation assays. Using the Comet assay, radiation of Ewing sarcoma cells with Ola, compared to without Ola, resulted in more DNA damage at 1 hour (mean tail moment 36–54 vs. 26–28) and sustained DNA damage at 24 hours (24–29 vs. 6–8). This DNA damage led to a 2.9- to 4.0-fold increase in apoptosis and a 1.6- to 2.4-fold increase in cell death. The effect of PARP-1 inhibition and radiation therapy on Ewing sarcoma cells was lost when EWS-FLI1 was silenced by shRNA. A small dose of radiation therapy (4 Gy), when combined with PARP-1 inhibition, stopped the growth of SK-N-MC flank tumors xenografts. In conclusion, PARP-1 inhibition in Ewing sarcomas amplifies the level and duration of DNA damage caused by radiation therapy, leading to synergistic increases in apoptosis and cell death in a EWS-FLI1–dependent manner. Mol Cancer Ther; 12(11); 2591–600. ©2013 AACR.

[1]  R. Randall,et al.  Salient features of mesenchymal stem cells—implications for Ewing sarcoma modeling , 2013, Front. Oncol..

[2]  A. Chen,et al.  Molecular Pathways: Targeting PARP in Cancer Treatment , 2012, Clinical Cancer Research.

[3]  Arul M Chinnaiyan,et al.  PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. , 2012, Cancer research.

[4]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[5]  J. Bartek,et al.  More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance , 2011, Nature Cell Biology.

[6]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[7]  S. Bhide,et al.  Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. , 2010, Cancer treatment reviews.

[8]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[9]  Vladimir N Uversky,et al.  Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma , 2010, Clinical Cancer Research.

[10]  Torgny Stigbrand,et al.  Radiation-induced cell death mechanisms , 2010, Tumor Biology.

[11]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[12]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[13]  B. Lu.  Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models: P3-030 , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  T. Helleday,et al.  DNA double-strand break repair: from mechanistic understanding to cancer treatment. , 2007, DNA repair.

[15]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[16]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[17]  Fiorenza Ianzini,et al.  Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells , 2006, Cancer Cell International.

[18]  Ralf Janknecht,et al.  EWS-ETS oncoproteins: the linchpins of Ewing tumors. , 2005, Gene.

[19]  Christopher T Denny,et al.  Biology of EWS/ETS fusions in Ewing's family tumors , 2001, Oncogene.

[20]  I. Roninson,et al.  Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. , 2000, Cancer research.

[21]  Ukcccr.  UKCCCR Guidelines for the Use of Cell Lines in Cancer Research , 2000, British Journal of Cancer.

[22]  T. Pawlik,et al.  Mouse endostatin inhibits the formation of lung and liver metastases. , 1999, Cancer research.

[23]  S. Sailer.  The Role of Radiation Therapy in Localized Ewing's Sarcoma , 1997 .

[24]  J. Ewing.  Diffuse endothelioma of bone , 1972 .

[25]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[26]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[27]  Sailer.  The Role of Radiation Therapy in Localized Ewing' Sarcoma. , 1997, Seminars in radiation oncology.

[28]  K. Bhatia,et al.  Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. , 1990, Cancer research.

[29]  J. Ewing.  Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. , 1972, CA: a cancer journal for clinicians.